LinkedIn
WebsiteIntroduction
OMEROS CORP (ticker: OMER) is a clinical-stage biopharmaceutical company based in Seattle, Washington. Founded in 1994, the firm focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for immunologic diseases and orphan indications. Its lead candidate, narsoplimab (OMS721/MASP-2), targets hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA) and is in Phase II trials for COVID-19 and acute respiratory distress syndrome.
Corporate Structure
OMEROS operates as a public company listed on NASDAQ (exchange code: NAS). The firm employs between 51 and 200 people and maintains its headquarters in Seattle. Its corporate structure includes research and clinical teams dedicated to complement pathway disorders, with additional groups overseeing regulatory affairs, finance, and corporate development.
Biopharmaceuticals by little plant
Developments and News
- Stock Performance: As of October 15, 2025, OMEROS shares traded at USD 10.33, reflecting a 151.95 percent increase from the prior reference price, on a volume of 6,960,183 shares.
- FDA Review of Narsoplimab: On September 25, 2025, the U.S. Food and Drug Administration set a target date to decide on the Biologics License Application (BLA) for narsoplimab. Following OMEROS’ submission of additional data, the agency extended its decision deadline to December 26, 2025, with labeling discussions slated to begin no later than October 2025, assuming no major deficiencies are identified.
- Novo Nordisk Agreement: OMEROS and Novo Nordisk entered an asset purchase and license agreement for OMEROS’ clinical-stage MASP-3 inhibitor, zaltenibart. The deal has a potential value of up to USD 2.1 billion, including upfront and milestone payments as well as royalties.
- Scientific Presentations: During the week of April 26, 2025, OMEROS attended the American Association for Cancer Research (AACR) Annual Meeting in Chicago to present its oncology program.
- SEC Filings: On August 14, 2025, OMEROS filed its Form 10-Q, providing second-quarter financial results. On October 15, 2025, the company submitted a Form 8-K disclosing material updates under Items 1.01, 8.01, and 9.01.
Financial and Strategic Analysis
According to Yahoo Finance, OMEROS’ estimated fair value per share is USD 4.10, indicating that the current trading price exceeds this model. Dividend, hiring, and insider sentiment scores all register at zero on a 0–100 scale, indicating minimal distributions, flat employment trends, and limited insider trading activity. Strategically, OMEROS is focusing its resources on its MASP inhibitor platform. With narsoplimab advancing through regulatory review and zaltenibart progressing toward a Phase III trial in paroxysmal nocturnal hemoglobinuria, the company is also exploring partnership opportunities for its other assets, including a long-acting MASP-2 inhibitor (OMS1029).
Market Position and Industry Context
OMEROS operates in the competitive biotech sector, where companies aim to address unmet needs in immunologic and complement-driven disorders. Currently, there is no approved therapy for TA-TMA, positioning narsoplimab as a potential treatment option if approved. The firm’s pipeline also includes candidates for rare diseases, such as complement 3 glomerulopathy and compulsive disorders. The collaboration with Novo Nordisk reflects a trend within the sector toward partnerships that facilitate late-stage development and distribution.
tl;dr
- FDA extended its BLA decision on narsoplimab to December 26, 2025, with label discussions to start by October 2025.
- OMEROS agreed to sell and license its MASP-3 inhibitor to Novo Nordisk for up to USD 2.1 billion plus royalties.
- Shares are trading at USD 10.33 (up 151.95 percent), above a modeled fair value of USD 4.10.
- Key regulatory and partnership milestones are expected through year-end 2025 and into 2026.
